Webinars
3D iPSC Culture: RocketCell™ 3D iPSC Growth Kit – An All-in-one Xeno-Free Platform
Discover how an integrated, xeno-free platform can accelerate your path to reproducible, clinically aligned 3D iPSC models.
Induced pluripotent stem cells (iPSCs) provide a powerful foundation for disease modeling, organoid development, and cell therapy applications. However, most iPSC research is still performed in two-dimensional (2D) systems that fail to fully recapitulate native tissue architecture and cellular interactions.
While three-dimensional (3D) iPSC culture and scale-up have been widely discussed as essential next steps for advanced cell modeling and regenerative medicine, the lack of standardized, integrated workflows has remained a major barrier. Researchers are often required to source, optimize, and validate disparate matrices, media, and supplements —resulting in high variability, limited reproducibility, and significant time investment.
In this webinar, we introduce the RocketCell™ 3D iPSC Xeno-Free Complete Growth Kit—an all-in-one, fully defined platform designed to simplify and standardize 3D iPSC culture and expansion. This integrated system combines a synthetic VitroGel® STEM hydrogel matrix with optimized xeno-free media, supplements, and a cell viability enhancer, eliminating the need for fragmented workflows and extensive optimization.
We will demonstrate a step-by-step approach for seamlessly transitioning iPSCs from 2D to 3D culture using this unified platform. Attendees will learn how to establish robust, reproducible 3D iPSC cultures that maintain pluripotency, long-term viability, and scalability with 10X cell density compared to the traditional culture method. We will also highlight compatibility with routine assays, immunostaining, and high-resolution 3D imaging workflows.
Supported by validated protocols and multi-line iPSC data, this presentation will show how the RocketCell™ platform enables researchers to move beyond trial-and-error and adopt a standardized foundation for downstream organoid generation, multilineage differentiation, and translational applications.
KEY TAKEAWAYS
- 3D, xeno-free iPSC culture provides a more physiologically relevant foundation for disease modeling, organoid generation, and translational research compared to traditional 2D systems.
- The RocketCell™ 3D iPSC Kit delivers a standardized, all-in-one solution that supports high-density expansion while maintaining pluripotency, long-term viability, and reproducibility.
- All-in-one kit, end-to-end workflows eliminate trial-and-error, enabling researchers to transition from 2D to 3D culture quickly and confidently.
- Scalable, imaging-compatible 3D platforms accelerate downstream applications, including multilineage differentiation, functional assays, and clinically aligned development.
PRESENTER
Rick Cohen, Ph.D.
TheWell Bioscience
Principal Scientist
Dr. Cohen earned his bachelor’s degree in Biochemistry and his doctorate in Pharmacology and Therapeutics from McGill University in Montreal. He conducted early research as a Visiting Scientist at Albert Einstein College of Medicine in the laboratory of Dr. William Norton, a pioneer in myelin biology, followed by a five-year postdoctoral fellowship in neurogenetics at the NIH (NINDS).
In 2001, Dr. Cohen joined the Coriell Institute for Medical Research, where he developed standardized protocols for the isolation, characterization, and differentiation of mesenchymal stem cells from cord blood, placenta, and bone marrow. In 2006, he established New Jersey’s first human embryonic stem cell laboratory and training program in collaboration with Dr. Joseph Itzkovitz of the Technion–Israel Institute of Technology.
Dr. Cohen later moved to Rutgers University, where he led intensive human embryonic stem cell training courses, educating over 100 scientists from academia and industry. He also directed the NJ State-funded Stem Cell Core Facility, contributed to collaborative neuroscience research, and mentored graduate students, postdoctoral fellows, and undergraduate researchers. His work during this period resulted in multiple publications in stem cell biology, including iPSC and mesenchymal stem cell research, as well as nanoparticle-based growth factor technologies.
In subsequent years, Dr. Cohen developed viral and non-integrating methods for iPSC generation, protocols for differentiating functional dopaminergic neurons, and recombinant nanoparticle growth factors for wound repair. Prior to leaving Rutgers in late 2024, he also engineered bovine myoblasts and iPSCs for 3D-printed cultivated meat applications.
In late 2024, Dr. Cohen joined TheWell Bioscience as Principal Scientist, where he is focused on translating decades of 2D cell culture expertise into advanced 3D cell culture platforms.
